Last reviewed · How we verify

ECTEINASCIDIN 743 — Competitive Intelligence Brief

ECTEINASCIDIN 743 (ECTEINASCIDIN 743) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

phase 1 Small molecule Live · refreshed every 30 min

Target snapshot

ECTEINASCIDIN 743 (ECTEINASCIDIN 743) — Children's Oncology Group. Binds to the minor groove of DNA, causing DNA strand breaks and disrupting DNA repair mechanisms and transcription.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ECTEINASCIDIN 743 TARGET ECTEINASCIDIN 743 Children's Oncology Group phase 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ECTEINASCIDIN 743 — Competitive Intelligence Brief. https://druglandscape.com/ci/ecteinascidin-743. Accessed 2026-05-21.

Build your own brief

Pick any drug + add comparators: